A Preview Of Taysha Gene Therapies's Earnings
Portfolio Pulse from Benzinga Insights
Taysha Gene Therapies (NASDAQ:TSHA) is scheduled to release its quarterly earnings report on Tuesday, 2023-11-14, with an estimated EPS of $-0.17. Investors are looking for an earnings beat and positive guidance for the next quarter. Historically, TSHA's stock price has been affected more by guidance than earnings beats or misses. Last quarter, TSHA missed the EPS estimate by $0.07, resulting in a 2.35% increase in share price the following day. Over the last year, TSHA shares have declined by 31.59%.
November 13, 2023 | 3:02 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Taysha Gene Therapies is expected to report an EPS of $-0.17 for the latest quarter. Positive guidance could influence the stock positively, while a miss in earnings could lead to a negative impact.
The short-term impact on TSHA's stock will likely depend on whether the company beats the earnings estimate and provides positive guidance. Historically, guidance has had a more significant impact on the stock price than earnings results. However, given the stock's decline over the past year, investor sentiment may already be bearish, which could moderate the impact of the earnings report.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100